The CenterWatch Monthly, October 2011

Tuesday, October 4, 2011 11:01 AM

Sponsors take action to reduce protocol amendments

Protocol amendments commonly have been considered an inconvenient—but inevitable—part of drug development. A recent Tufts CSDD study found each amended protocol has an average of 2.3 amendments, resulting in four months of additional time to implement. On average, the study found it cost nearly a half-million dollars to implement a single protocol amendment. It indicated a large proportion of them could be prevented. Now, a few leading biopharmaceutical companies have launched efforts to reduce and prevent certain amendments through better protocol designs and...

 

EHR integration could change the game for clinical research

A few short years ago clinical research sites struggled with moving their paper systems to electronic form. The automation added efficiencies, but information often had to be re-entered into different systems, adding errors and taking time from patient care. Now, a different kind of electronic integration is poised to redefine how sites conduct research studies and gather data. Proponents say the electronic health record can eliminate duplication of data, reduce the overwhelming administrative costs and create...

 

Eye On Isis Pharmaceuticals

Isis Pharmaceuticals focuses on antisense drug development, applicable to many different disease targets. Its strategy includes licensing its drugs to partners before late-phase development and marketing. This allows Isis to direct its capital to discovery and early development rather than commercialization and sales, while still benefiting from licensing fees, equity purchase payments, milestone payments and R&D funding. To protect its status as an innovator in RNA-based drug discovery and development, Isis has implemented a patent strategy...

To read the full articles for this issue of The CenterWatch Monthly, please click here for subscription information.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

July 21

As job growth in drug development sector soars, more employees are seeking new opportunities

U.K. study: Prisoners should have the right to participatein clinical trials on moral grounds, for healthcare access

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

IRB market consolidating rapidly
Private equity driving a new commercial ethical review landscape

Lessons learned from medical device trials
Smaller, faster, more flexible trials hold important insights for pharmaceutical innovation

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

CRO market poised for growth and consolidation
Sponsors expanding pipelines, shrinking infrastructure fuel strategic outsourcing

Strategies for success evolving in phase I space
Sites see increasing complexity, more patients, greater focus on efficacy

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs